TECH News & Events

Reports Q3 revenue $311.42M, consensus $316.06M. "The Bio-Techne team delivered solid execution amid a mixed end-market environment," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Large pharma again led results with the sixth consecutive quarter of double-digit growth, supported by momentum in Asia and stabilizing U.S. academic demand. While biotech funding remains healthy, it has not yet translated into broad-based demand across our portfolio."

Bio-Techne Corporation announced that the Ella benchtop immunoassay platform has received CE-IVD marking and is now available for sale in the European Union, E.U.. This achievement brings Ella's hallmark ease of use, speed and reproducibility to clinical settings, helping laboratories streamline workflows and support timely decision-making. The platform is compatible with Simple Plex assays, which remain for research use only, and are powered by R&D Systems antibodies and proteins. "Ella's CE-IVD certification marks a significant step forward in advancing precision diagnostics," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "It reflects our commitment to providing innovative tools that enhance clinical decision-making and improve patient outcomes."